Hemogenyx Net Borrowings vs Net Income Analysis
HEMO Stock | 343.40 20.90 6.48% |
Hemogenyx Pharmaceuticals financial indicator trend analysis is much more than just examining Hemogenyx Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hemogenyx Pharmaceuticals is a good investment. Please check the relationship between Hemogenyx Pharmaceuticals Net Borrowings and its Net Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Net Borrowings vs Net Income
Net Borrowings vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hemogenyx Pharmaceuticals Net Borrowings account and Net Income. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Hemogenyx Pharmaceuticals' Net Borrowings and Net Income is 0.86. Overlapping area represents the amount of variation of Net Borrowings that can explain the historical movement of Net Income in the same time period over historical financial statements of Hemogenyx Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Hemogenyx Pharmaceuticals' Net Borrowings and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Borrowings of Hemogenyx Pharmaceuticals PLC are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Net Borrowings i.e., Hemogenyx Pharmaceuticals' Net Borrowings and Net Income go up and down completely randomly.
Correlation Coefficient | 0.86 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Hemogenyx Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Hemogenyx Pharmaceuticals PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Hemogenyx Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hemogenyx Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Selling General Administrative is likely to gain to about 5.2 M in 2024. Issuance Of Capital Stock is likely to gain to about 5.3 M in 2024
Hemogenyx Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Hemogenyx Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hemogenyx Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.0M | 2.7M | 8.5M | 7.1M | 6.1M | 3.5M | |
Total Stockholder Equity | (346.5K) | 890.8K | 8.2M | 3.3M | 2.8M | 2.1M | |
Net Debt | 758.6K | (184.2K) | (6.8M) | 890.1K | 1.7M | 1.8M | |
Retained Earnings | (6.0M) | (8.0M) | (13.1M) | (17.1M) | (23.8M) | (22.6M) | |
Cash | 498.7K | 1.8M | 6.8M | 2.5M | 1.2M | 1.9M | |
Cash And Short Term Investments | 498.7K | 1.8M | 6.8M | 2.5M | 1.2M | 1.9M | |
Common Stock Total Equity | 3.6M | 3.6M | 3.6M | 4.3M | 5.0M | 2.9M | |
Common Stock Shares Outstanding | 360.7M | 414.8M | 774.0M | 979.7M | 1.1B | 1.2B | |
Liabilities And Stockholders Equity | 1.0M | 2.7M | 8.5M | 7.1M | 6.1M | 3.5M | |
Other Current Assets | 55.8K | 105.0K | 298.2K | 62.0K | 922.0K | 968.1K | |
Total Current Assets | 554.5K | 1.9M | 7.1M | 2.6M | 2.2M | 2.1M | |
Common Stock | 3.6M | 3.6M | 4.3M | 9.8M | 11.8M | 12.3M | |
Short Long Term Debt Total | 1.3M | 1.6M | 10.2K | 3.4M | 2.9M | 1.5M | |
Other Current Liab | 80.3K | 47.5K | 46.9K | 51.9K | 77.3K | 71.2K | |
Total Current Liabilities | 181.6K | 1.8M | 352.8K | 748.4K | 652.1K | 526.2K | |
Net Tangible Assets | 686.4K | (608.6K) | 635.9K | 7.8M | 8.9M | 9.4M | |
Accounts Payable | 61.4K | 113.2K | 295.8K | 374.3K | 301.7K | 154.9K | |
Non Current Assets Total | 495.4K | 747.3K | 1.4M | 4.5M | 3.9M | 4.1M | |
Non Current Liabilities Total | 1.2M | 10.0K | 306.0K | 3.1M | 2.7M | 2.8M | |
Other Stockholder Equity | 7.7M | 10.0M | 23.0M | 16.8M | 14.9M | 10.1M | |
Total Liab | 1.4M | 1.8M | 352.8K | 3.8M | 3.3M | 3.5M | |
Accumulated Other Comprehensive Income | 452.5K | 756.9K | 878.3K | (58.8K) | 1.1M | 1.1M | |
Intangible Assets | 272.8K | 262.1K | 255.0K | 441.5K | 470.2K | 356.6K | |
Property Plant And Equipment Net | 233.4K | 268.7K | 797.1K | 3.9M | 3.3M | 3.5M | |
Non Currrent Assets Other | 0.0 | 223.6K | 142.6K | 140.8K | 153.7K | 155.6K | |
Net Receivables | 32.3K | 56.3K | 7.5K | 9.8K | 5.1K | 4.9K | |
Property Plant Equipment | 173.9K | 233.4K | 268.7K | 797.1K | 916.7K | 962.5K | |
Net Invested Capital | 797.6K | 2.5M | 8.2M | 3.3M | 2.8M | 3.4M | |
Property Plant And Equipment Gross | 233.4K | 268.7K | 1.1M | 4.5M | 4.0M | 4.2M | |
Net Working Capital | 372.9K | 138.4K | 6.8M | 1.8M | 1.5M | 2.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hemogenyx Stock Analysis
When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.